Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:56 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
NCT00601978 · Novartis Pharmaceuticals · PHASE4 · withdrawn · last registry update 2012-04-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision brand strategy; no patients enrolled” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-04-04Results posted on the registry: University of Cincinnati, Topiramate + Placebo (NCT00394095)
- 2012-10-29Phase 3 first posted: Forest Laboratories, Cariprazine + Placebo (NCT01715805)
- 2012-10-08Results posted on the registry: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., pregabalin + placebo (NCT00991276)
- 2012-09-27Results posted on the registry: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., placebo and pregabalin + pramipexol (NCT00806026)
- 2012-09-19Phase 3 first posted: Eli Lilly and Company, Olanzapine + Fluoxetine (NCT01687478)
- 2012-06-18Phase 3 first posted: Knopp Biosciences, Dexpramipexole (NCT01622088)
- 2012-06-12Phase 3 first posted: Organon and Co, Asenapine + Placebo Asenapine (NCT01617187)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision